A short item on next-generation weight loss drugs reported to outperform Ozempic. Few details beyond the headline.
Recap by typeshit. Full story at BusinessWorld Online.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
A new 'In Discussion With' episode features Sehar Shahid on what makes losing weight difficult. Little else is shared beyond the topic.
An investor angle arguing Lilly's triple agonist could become a bigger growth driver than Zepbound, ahead of the company's quarterly report.
Loading…